by Dana-Farber Cancer Institute Graphical Abstract. Credit: Molecular Cell (2023). DOI: 10.1016/j.molcel.2023.02.026 Custom-made to attack cancer cells, CAR T-cell therapies have opened a new era in the treatment of human cancers, particularly, in hematologic malignancies. All too often, however, they display a frustrating trait inherited from the body’s own immune system cells: a drastic loss of cancer-fighting...
